Introduction
The ubiquitin-proteasome pathway is the major qualitycontrol pathway for newly synthesized proteins in every eukaryotic cell. The 26S proteasome is a large (2.5 MDa), multi-subunit, ATP-dependent proteolytic complex that processively degrades proteins into peptides. It consists of a hollow cylindrical 20S proteolytic core and one or two 19S regulatory particles (RP). The 19S RP recognizes ubiquitylated substrates and prepares them for proteolysis, which occurs inside the 20S core. The 20S cores are hollow cylindrical structures comprising two pairs of 14 different polypeptides arranged in four stacked rings. Three subunits on each inner ring carry catalytic residues for the proteolytic sites ( Figure 1 ). The catalytic residues of the chymotrypsin-like sites are located on b5 subunits and cleave peptide bonds predominantly after hydrophobic residues. The caspase-like sites are located on the b1 subunits which cleave peptide bonds after acidic residues. The third pair of sites is located on the b2 subunits. They cleave after basic residues and are referred to as trypsin-like sites. The lymphoid tissues contain immunoproteasomes, in which b5, b2, b1 subunits are replaced with b5i (LMP7), b2i (MECL1), b1i (LMP2) subunits, respectively ( Figure 1 ). Moreover, epithelial cells in the cortex of the thymus express thymoproteasomes consisting of the active site subunits b5t, b2i and b1i. Here we describe the recent development of inhibitors for these tissue specific proteasome variants and how they can be exploited for immunomodulation in antigen processing and the therapy of autoimmune diseases.
The majority of proteasome inhibitors inhibit multiple active sites
The inhibitors of proteolytic sites of the 20S core have served as indispensible tools to identify proteasome substrates and establish proteasome involvement in a variety of biochemical, immunological, and physiological processes for two decades (see [1 ] for review). One of the earliest findings with these inhibitors was that transformed cells rapidly undergo apoptosis upon treatment with proteasome inhibitors, while much higher concentrations are needed to induce death of their non-transformed counterparts. These discoveries stimulated development of proteasome inhibitors as anti-neoplastic agents and, in 2003, bortezomib was approved by the FDA for the treatment of multiple myeloma. It took few additional years to realize that exquisite sensitivity of this particular cancer to proteasome inhibitors is caused by an exceptionally high load on the proteasome in myeloma cells, which secrete large amounts of immunoglobulins [2] . In 2012, another proteasome inhibitor, carfilzomib [3] , has been approved for the treatment of multiple myeloma.
Because results of site-directed mutagenesis in yeast revealed that the chymotrypsin-like sites are most important in protein degradation, and because of the ability of hydrophobic peptides to enter cells, the various synthetic proteasome inhibitors were optimized according to their capacity to block the b5 sites, which cleave preferentially after hydrophobic residues [1 ] . The primary target of all natural product inhibitors is also the chymotrypsin-like site. All compounds targeting chymotrypsin-like sires (e.g., MG-132, bortezomib, epoxomicin, clasro-lactacysrin-13-lacrone) effectively inhibit protein degradation inside the cells. However, none of these inhibirors can be considered chymotrypsin-like sires selective, and inhibition of protein degrada cion occurs at concentrations that co-inhibit either caspase-like or trypsin-like sites [4] , raising the possibility that contribution of these two sites tO protein degradation is larger than previously appreciated. This observation, together with the fact that borrezomib inhibits the caspase-like activity of the proteasome [4 6 ], stimulated the interest in the development of specific inhibirors of the individual active sires, ro be used as rools ro dissect contributions of individual sires ro protein degradation, and ro define their individual roles as targets for anti-neoplastic and ami-inflammatOry agents.
Subunit-specific proteasome inhibitors
The great majority of site-specific proteasome inhibirors consist of an elecrrophilic trap that interacts with the catalytic threonine at the N -terminus of mature 13-type subunits and a peptide moiety. A peptide epoxykerone YU-101 ( Figure 2A ) was the first highly potent and specific inhibitor of the chymotrypsin-like sites to be developed [7] . Carfilzomib is a derivative ofthis inh ibiror [3] . It is the most specific inhibitor of the chymotrypsinlike sites among FDA-approved agents or agents undergoing clinical trials. NC-005 is even more specific than YU-101 and carfilzomib [8] whiJe IPSI-001 inhibits both 131i and 135i [9] . Further efforts ro improve selectivity have challenged the common dogma that active-site specificity is determined by the peptide portion of the inhibiror but not by the active-site elecrrophile. It was found that replacing epoxyketone in NC-005 ( Figure 2A ) with a vinyl sulfone moiety increases specificity for the chymotrypsin-like sites [10•] . Finally, utilization of 17 fluorinated amino acids had led ro another compound with improved specificity for the chymotrypsin-like activity, LU-005 (F igure 2A) [11] .
Systematic modification of the peptide epoxykerone scaffold led to the development of the 135-specific inhibitor PR-825 ( Figure 2F ), and two 135i inhibitors, PR-924 and PR-957 (later renamed ONX-0914, F igure 2E) [1 2. ,13
Replacement of phenyl side chains in the P1 position in PR-924 and PR-957 with a cyclohexyl generated the highly selective 135i inhibitors LU-015i and LU-005i ( Figure 2E ) [14] . Oxathiazolones ( Figure 2E ) were first discovered as inhibitOrs of mycobacterial proteasomes but a recent study revealed that they show considerable selectivity roward 135i over 135 sites [15•] . The residues involved in the stabilization of the oxathiazolone covalent adduces with the mycobacterial proteasomes and the 135i site of human immunoproteasomes are similar. Oxathiazolones have a short half-life in aqueous solutions [1 5•] , which may limit their in vivo activity. Lascly, a number of non-peptide inhibitors of 135i were identified recencly by virtual screening [16] .
YU-102 was the first inhibitOr of caspase-like sites to be developed [17] , followed by the more specific NC-001 and compound 1 [18] (F igure 2C). All three epoxyketones inhibit both the 131 and 131i sites. Replacement of the isopropyl side chain in the P1 position with a cyclohexyl moiety, and fluorine substitutions in the 3-postion of the P3-Pro residue converted NC-001 into the 131i-specific inhibitor LU-001i ( Figure 2D ). LU-001i is more 131i-specific than another peptide epoxykerone UK-101 ( Figure 2D ), which also inhibitS 135i sites [14, 19] . Dipeptide boronate ML604440 is a more potent and specific inhjbitor of 131i sites [20] . All inhibitors are cell-permeable.
A bigger challenge has been the development of cellpermeable inhibitors of the trypsin-like sites. The first specific inhibitors of these sites were cell impermeable [21, 22] . Another structural class, peptide vinyl esters [23] , irutially reported as ceiJ-permeable inhibirors of the trypsin-like sires, did not have any inhibitory activirywhen resynthesized by another group [10•1. FinaJly two cellpermeable peptide epoxyketones, NC-002 and NC-022 ( Figure 2B ), were discovered a few years ago [24] . They were folJowed by the more potent vinyl sulfone LU-102 ( Figure 2B ), which also has a better cell permeability [25 •• ] . Just as with inhibirors of the chymotrypsin-like sites, these studies revealed that replacing the epoxyketone elecrrophiJe with vinyl sulfone dramatically increases the specificity of compounds for its primary target.
Most of these specific inhibitOrs were irutiaiJy used to define the role of different active sites as drug targets in cancer. For example, it was found that increasing the specificity of compounds for the chymotrypsin-like sites dramatically decreases the cytotoxicity for HeLa cells [10 ] . Inhibitors of trypsin-like and caspase-like sites, while not cytotoxic to cells when used as a single agent, sensitized multiple myeloma cells to inhibitors of the chymotrypsin-like sites, e.g. NC-005 and LU-005 [8] . Furthermore, inhibitors of the trypsin-like sites selectively sensitized myeloma cells to bortezomib and carfilzomib [24] . In other words, cytotoxicity was observed only when two types of active sites were inhibited. The lack of cytotoxic effect of site-specific inhibitors offers opportunities for using them for immunomodulation.
Selective inhibition of the immunoproteasome allows in vivo modulation of antigen processing and T cell generation
When cells are stimulated with interferon (IFN)-g and tumor necrosis factor (TNF)-a, they produce vast amounts of the inducible b-type subunits b1i, b2i, and b5i. In such a pro-inflammatory environment virtually all newly synthesized 20S proteasomes incorporate these inducible subunits rather than their constitutive homologues b1, b2, and b5 to form immunoproteasomes. In mice infected with viruses, bacteria or fungi it has been shown that in the liver and other organs (but not the brain [26] ) constitutive proteasomes are largely replaced by immunoproteasomes [27, 28] . The proteasome is centrally involved in the generation of peptide ligands of major histocompatibility complex (MHC) class I molecules which are recognized by the antigen receptors of cytotoxic T lymphocytes (CTL) (Figure 3) . Under stimulation with IFN-g or TNF-a the cell surface expression of class I molecules is up-regulated approximately tenfold. The immunoproteasome is required to produce this surplus of class I peptide ligands needed because deletion of b5i alone or all three immunosubunits (b1i, b2i, b5i) rogerher reduces class I surface expression in spleen, lymph nodes and thymus by approximately SO% [29] . Moreover, rhe trearmenr of cells or mice with rhe I3Si selective inhjbiror ONX-0914 (formerly called PR-957) leads ro a similar reduction in MHC class I surface expression indicating that I3Si is pivotal for the elevated generation of class I ligands [13••,30] . ONX-0914 exertS rhis effect in wild type but not in 135i_, _ mice indicating an on target effect of this first selective inhibiror of rhe immunoproteasome.
The mosr likely reason why immunoproteasomes produce more or better suited class I ligands is rhat compared ro constitutive proreasomes they alter the cleavage preferences such rhat class I ligands with higher binding affinities for the peptide binding groove of class I molecules are generated. The caspase-like activity of 131, for example, produces weaker class I ligands than the chymotrypsin-like activity of 131i because their C-rerminal anchor residues must possess hydrophobic or basic bur nor acidic side chains ro enable right binding imo the peptide cleft of class I molecules [31] . Since 135 and I3Si both exert a chymotrypsin-like activity, the requirement for this exchange was Jess obvious. However, the recently reported high resolution structures of mouse constitutiveand immunoproteasomes revealed that the 81 substrate 19 pocket of I3Si accommodates better bulky aliphatic and aromatic hydrophobic side chains [32••1 which are most frequently found in peptides eluted from class I molecules. In spite of this valuable structural insight, the consequence of replacing 132 with 132i has remained elusive as they both harbor an equivalenr trypsin-like activity [33, 34] and no obvious differences between the peptide binding pockets of 132 and 132i have been noted. Accordingly, the generation of selective inhibirors for 132 and 132i will be a formjdable task.
The effect of immunoproteasome deficiency or inhibition on the bulk supply of MHC class I ligands on immune defence is limited. Mice lacking the inducible subunits are immunocompetenr except for an enhanced susceptibiljry ro experimenraJ infections with Toxoplasma g01rdii [35] and Listeria mo11ocytoge11es [36] . However, on the level of rhe unique epitope the presence of immunoproteasomes can be crucial either because the activity of 131i, 132i, or I3Si is required for generating the epitope [37] or because epitope destruction through the constitutive subunits 131, 132, or 135 needs ro be prevented by replacement with rhe respective immuno-suburuts [20] . The importanr role ofimmunoproteasome subunits in defirung the repertoire of peptides presenred on MHC class I molecules has been underlined by the mass spectrometric analysis of peprides eluted from rwo class I molecules of splenocytes of wild type and 131i!l32i/135i triply gene deleted mjce [29] . The advenr of suburut specific inhibitOrs has tl1erefore enabled the pharmacological modulation of peptide anrigen generation and presentation as well as the developmenr and expansion of cognate T cells itt vivo [13••,30] . Whether this potential of subunit selective proreasome inhibitors can be exploited for pharmacological intervenrion with infectious or autoimmune diseases remains to be determined.
lmmunoproteasome subunits as novel targets for the suppression of autoimmunity
Accumulating evidence indicates that rhe immunoproteasome plays a cruciaJ role for the pathogenesis of several autoimmune diseases and that this role is unrelated to the MHC class I anrigen processing pathway. It was found that both, CDS+ CTLs and CD4+ T helper cells, need the immunoproteasome ro survive in a pro-inflammatory environmenr [38] . Consequenrly, the inhibition of I3Si, 132i, or 131i may be a means to ameliorate pro-inflammatOry autoimmune diseases which rely on these cells. In fact, the treatmenr of mice with the I3Si selective inhibitor ONX-0914 prevenred rhe developmenr or progression of experimenral artluitis [13••1, diabetes [13 •• ] , inflammatory bowel disease [39] , systemic lupus erythematOsus [40] , and experimental autoimmune encephalomyelitis (EAE) [41••1 in preclinical mouse models. Unexpectedly, I3Si-deficienr mice did not display the same protection profile as ONX-0914 treated wild type mjce in each ofthese models. Both, I3Si inhibition and deficiency protected mice from dextrane sulfate sodium (DSS) induced colitis indicating that b5i plays an essential role in disease development which cannot be sustained by b5 activity [39, 42] . In the multiple sclerosis model EAE, in contrast, protection from disease progression and relapse was observed in ONX-0914 treated wild type but not in b5i À/À mice [41 ] . However, the treatment of b5i
but not wild type mice with the b5-selective inhibitor PR-825 suppressed EAE. Since b5 completely occupies the b5/b5i position in the proteasome of b5i À/À mice, this result strongly suggests that inhibition with PR-825 suppressed the chymotrypsin-like activity in b5i À/À mice to a degree which blocked the pathogenic cells. This interpretation is consistent with high immunoproteasome expression in bone marrow-derived cells which cause the disease. The lesson learnt from these experiments is that b5i selective inhibitors may not only be of therapeutic potential for diseases which rely on a nonredundant function of b5i but for all pro-inflammatory diseases which rely on leukocytes expressing high levels of immunoproteasomes.
At first sight one may argue that more general inhibitors of the proteasomal chymotrypsin-like activity could be applied. However, immunoproteasomes are largely confined to sites of inflammation and leukocytes and therefore b5i selective therapy will block them and not the majority of tissues which express mainly constitutive proteasomes. Consistently, it has been shown that ONX-0914 is effective tenfold below its maximally tolerated dose while inhibitors of b5i and b5 like bortezomib or carfilzomib have to be applied at the maximally tolerated dose. The resulting adverse effects are acceptable for the treatment of neoplastic diseases like multiple myeloma or mantle cell lymphoma but are probably too severe for the long term treatment of chronic autoimmune diseases.
Conclusion
The selective inhibition of proteasome subunits is an interesting approach especially if specific subunits of the immunoproteasome but perhaps also of the thymoproteasome [37, 43] are targeted. The high resolution structures of the 20S constitutive-and immunoproteasome have suggested that immunoproteasomes should be druggable and the first inhibitor of b5i has proven the principle in preclinical models of autoimmunity. Immunoproteasomes are expressed in lymphocytes, antigen presenting cells and innate immune cells and it will be important to elucidate which cells are primarily targeted in which type of disease. A similarly big challenge will be to find out how the immunoproteasome is mechanistically involved on a molecular level in the pathogenesis especially in those disease models which rely on a non-redundant function of the immunoproteasome. Hopefully site specific inhibitors of the immunoproteasome will help to identify selective substrates or cleavage activities of the immunoproteasome. Based on the reported preclinical results research teams in academia and pharmaceutical industry have intensified the search for selective proteasome inhibitors which will hopefully soon be subjected to clinical testing.
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